Mineralys Therapeutics, Inc. surged 80% after AstraZeneca's rival data, with lorundrostat now viewed as a potential best-in-class hypertension therapy. Lorundrostat's Phase 3 results show superior ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback